ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Monday, November 10, 2025 at 5:30 a.m. PT / 8:30 a.m. ET to discuss third quarter 2025 financial results and business highlights. Dial-in details are available by registering for the event.
Investors can access the live webcast and slides on the company’s Investors & Media > Events & Presentations page. A replay of the webcast will be available for 30 days after the event.
ARS Pharmaceuticals (Nasdaq: SPRY) terrà una conference call e una webcast il lunedì 10 novembre 2025 alle 5:30 a.m. PT / 8:30 a.m. ET per discutere i risultati finanziari del terzo trimestre 2025 e i principali dati aziendali. I dettagli per l'accesso telefonico sono disponibili registrandosi all'evento.
Gli investitori possono accedere alla webcast in diretta e alle slide sulla pagina Investors & Media > Events & Presentations dell'azienda. Una replica della webcast sarà disponibile per 30 giorni dopo l'evento.
ARS Pharmaceuticals (Nasdaq: SPRY) realizará una llamada de conferencia y webcast el lunes 10 de noviembre de 2025 a las 5:30 a. m. PT / 8:30 a. m. ET para discutir los resultados financieros del tercer trimestre de 2025 y los aspectos destacados del negocio. Los detalles para marcar están disponibles al registrarse para el evento.
Los inversores pueden acceder al webcast en vivo y a las diapositivas en la página de la empresa Inversores & Medios > Eventos & Presentaciones. Una reproducción del webcast estará disponible durante 30 días después del evento.
ARS Pharmaceuticals (Nasdaq: SPRY)는 제3분기 2025년 재무 실적 발표 및 비즈니스 하이라이트를 논의하기 위해 2025년 11월 10일 월요일 오전 5:30 PT / 오전 8:30 ET에 컨퍼런스 콜 및 웹캐스트를 주최합니다. 전화 접속 세부 정보는 이벤트 등록을 통해 이용 가능합니다.
투자자들은 회사의 투자자 및 미디어 > 이벤트 및 프레젠테이션 페이지에서 라이브 웹캐스트 및 슬라이드를 접속할 수 있습니다. 이벤트 후 30일 동안 웹캐스트의 리플레이를 이용하실 수 있습니다.
ARS Pharmaceuticals (Nasdaq: SPRY) organisera une conférence téléphonique et une webdiffusion le lundi 10 novembre 2025 à 5h30 PT / 8h30 ET pour discuter des résultats financiers du troisième trimestre 2025 et des points forts de l'activité. Les détails de connexion sont disponibles en vous inscrivant pour l'événement.
Les investisseurs peuvent accéder à la webdiffusion en direct et aux diapositives sur la page de l'entreprise Investors & Media > Events & Presentations. Une rediffusion de la webdiffusion sera disponible pendant 30 jours après l'événement.
ARS Pharmaceuticals (Nasdaq: SPRY) wird eine Telefonkonferenz und einen Webcast am Montag, 10. November 2025 um 5:30 Uhr PT / 8:30 Uhr ET abhalten, um die Finanzergebnisse des dritten Quartals 2025 und Geschäftshöhepunkte zu besprechen. Dial-in-Details erhalten Sie, indem Sie sich für die Veranstaltung anmelden.
Investoren können den Live-Webcast und die Folien auf der Seite des Unternehmens Investors & Media > Events & Presentations aufrufen. Eine Wiedergabe des Webcasts wird 30 Tage nach der Veranstaltung verfügbar sein.
ARS Pharmaceuticals (Nasdaq: SPRY) ستستضيف مؤتمرًا هاتفيًا وبثًا عبر الإنترنت في الاثنين 10 نوفمبر 2025 الساعة 5:30 صباحًا بتوقيت المحيط الهادئ / 8:30 صباحًا بتوقيت شرق الولايات المتحدة لمناقشة نتائج الربع الثالث من 2025 وأبرز النقاط الأعمال. تفاصيل الاتصال عبر الهاتف متاحة بالتسجيل للحدث.
يمكن للمستثمرين الوصول إلى البث المباشر عبر الويب والشرائح على صفحة الشركة المستثمرون والإعلام > الأحداث والعروض. سيكون للبث المعاد عرضه عبر الويب متاحًا لمدة 30 يومًا بعد الحدث.
- None.
- None.
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its third quarter 2025 financial results and business highlights.
Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com
Monique Allaire
THRUST
monique@thrustsc.com
Media Contact:
Christy Curran
Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
FAQ
When will ARS Pharmaceuticals (SPRY) report Q3 2025 results and hold its conference call?
How can I join the ARS Pharmaceuticals (SPRY) November 10, 2025 webcast?
Will ARS Pharmaceuticals (SPRY) make the Q3 2025 webcast available after the live event?
What topics will ARS Pharmaceuticals (SPRY) cover on the November 10, 2025 call?
Where can investors find slides and materials for the ARS Pharmaceuticals (SPRY) Q3 2025 presentation?
